Caprion Biosciences Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Caprion Biosciences Inc. - overview
Established
2000
Location
Montreal, QC, Canada
Primary Industry
Biotechnology
About
Founded in 2000 and based in Montreal, Canada, Caprion Biosciences Inc. specializes in advanced immunology and proteomics services, supporting drug development and immunotherapy initiatives for various industries. Caprion Biosciences Inc. is dedicated to providing immune monitoring, protein characterization, and tissue pathology solutions to support immunotherapy and drug development.
Founded in Montreal, Canada, by Martin Leblanc, the company has undergone significant changes, including a merger with management in July 2019, creating a global leader in its field. The firm has completed a total of 11 funding deals, with the latest being a Secondary Buyout amounting to USD 4. 50 mn, all raised over its operational years. The most recent deal was completed on July 31, 2019.
Caprion Biosciences Inc. provides comprehensive services in immune monitoring, protein characterization, and tissue pathology for immunotherapy and drug development. Their offerings include tailored solutions for businesses engaged in advanced research, enabling them to optimize therapeutic outcomes. The company's services cater to a wide array of clients, including pharmaceutical companies and research institutions, and are designed to enhance the efficacy of drug development processes.
Caprion Biosciences Inc. employs a subscription-based revenue model, allowing clients to access specialized tools and services for their research and development needs. Clients engage through direct subscriptions, gaining access to immune monitoring services and related resources. The firm's offerings are tailored to meet the complexity and scale of diverse client requirements, facilitating effective drug development and immunotherapy strategies.
Caprion Biosciences Inc. plans to leverage its recent merger to expand its product offerings in immune monitoring and protein characterization, targeting global markets with high demand for immunotherapy solutions. The firm aims to introduce new advanced services by the end of 2020, effectively enhancing its portfolio. The funds from the latest Secondary Buyout will be utilized to support these initiatives, solidifying its position as a leader in immunotherapy and drug development solutions.
Current Investors
CellCarta Inc.
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Diagnostic, Medical & Imaging Laboratories
Website
www.caprion.com
Company Stage
Merged
Total Amount Raised
Subscriber access only
Caprion Biosciences Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Caprion Biosciences Inc. | - | ||||||||
| Merger | Completed | Caprion Biosciences Inc., HistoGeneX N.V. | - | ||||||||
| Add-on | Completed | Serametrix Corporation | - | ||||||||
| Add-on | Completed | Primity Bio, Inc. | - | ||||||||
| Add-on | Completed | ImmuneHealth ASBL‘s immune monitoring laboratory | - |
Displaying 1 - 5 of 10
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.